Market Research Life Sciences Market Research Medical Devices Market Research Infusion Products Market Research

Allogeneic Stem Cell Market (Type: Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant, and Donor Lymphocyte Infusion [DLI]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 204 Pages Transparency Market Research Pvt. Ltd. August, 2023 TNPR18249887
Best Price Guarantee
Price from $5,795
Length 204 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date August, 2023
SKU TNPR18249887

Allogeneic Stem Cell Market (Type: Unmodified Stem Cell Transplant, T-cell Depleted Transplant, Cord Blood Transplant, and Donor Lymphocyte Infusion [DLI]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Allogeneic Stem Cell Market – Scope of Report

TMR’s report on the global allogeneic stem cell market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global allogeneic stem cell market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global allogeneic stem cell market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the allogeneic stem cell market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global allogeneic stem cell market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global allogeneic stem cell market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global allogeneic stem cell market.

The report delves into the competitive landscape of the global allogeneic stem cell market. Key players operating in the global allogeneic stem cell market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global allogeneic stem cell market profiled in this report.

Key Questions Answered in Global Allogeneic Stem Cell Market Report
  • What is the sales/revenue generated by allogeneic stem cell across all regions during the forecast period?
  • What are the opportunities in the global allogeneic stem cell market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Allogeneic Stem Cell Market – Research Objectives and Research Approach

The comprehensive report on the global allogeneic stem cell market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global allogeneic stem cell market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global allogeneic stem cell market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Allogeneic Stem Cell Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Allogeneic Stem Cell Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Insights on Trends in Allogeneic Stem Cell Transplantation
5.2. Technological Advancements
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Allogeneic Stem Cell Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Unmodified Stem Cell Transplant
6.3.2. T-cell Depleted Transplant
6.3.3. Cord Blood Transplant
6.3.4. Donor Lymphocyte Infusion (DLI)
6.4. Market Attractiveness Analysis, by Type
7. Global Allogeneic Stem Cell Market Analysis and Forecast, by Cell Source
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cell Source, 2017-2031
7.3.1. Bone Marrow
7.3.2. Peripheral Blood Stem Cell (PBSC)
7.3.3. Umbilical Cord Blood
7.3.4. Adipose Tissue
7.3.5. Others
7.4. Market Attractiveness Analysis, by Cell Source
8. Global Allogeneic Stem Cell Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Musculoskeletal Disease
8.3.2. Cardiovascular Disease
8.3.3. Autoimmune Disease
8.3.4. Cancer
8.3.5. GvHD
8.3.6. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Allogeneic Stem Cell Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospital
9.3.2. Ambulatory Surgical Center
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Allogeneic Stem Cell Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Allogeneic Stem Cell Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
11.2.1. Unmodified Stem Cell Transplant
11.2.2. T-cell Depleted Transplant
11.2.3. Cord Blood Transplant
11.2.4. Donor Lymphocyte Infusion (DLI)
11.3. Market Value Forecast, by Cell Source, 2017-2031
11.3.1. Bone Marrow
11.3.2. Peripheral Blood Stem Cell (PBSC)
11.3.3. Umbilical Cord Blood
11.3.4. Adipose Tissue
11.3.5. Others
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Musculoskeletal Disease
11.4.2. Cardiovascular Disease
11.4.3. Autoimmune Disease
11.4.4. Cancer
11.4.5. GvHD
11.4.6. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospital
11.5.2. Ambulatory Surgical Center
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Cell Source
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country/Sub-region
12. Europe Allogeneic Stem Cell Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
12.2.1. Unmodified Stem Cell Transplant
12.2.2. T-cell Depleted Transplant
12.2.3. Cord Blood Transplant
12.2.4. Donor Lymphocyte Infusion (DLI)
12.3. Market Value Forecast, by Cell Source, 2017-2031
12.3.1. Bone Marrow
12.3.2. Peripheral Blood Stem Cell (PBSC)
12.3.3. Umbilical Cord Blood
12.3.4. Adipose Tissue
12.3.5. Others
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Musculoskeletal Disease
12.4.2. Cardiovascular Disease
12.4.3. Autoimmune Disease
12.4.4. Cancer
12.4.5. GvHD
12.4.6. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospital
12.5.2. Ambulatory Surgical Center
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Cell Source
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Allogeneic Stem Cell Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. Unmodified Stem Cell Transplant
13.2.2. T-cell Depleted Transplant
13.2.3. Cord Blood Transplant
13.2.4. Donor Lymphocyte Infusion (DLI)
13.3. Market Value Forecast, by Cell Source, 2017-2031
13.3.1. Bone Marrow
13.3.2. Peripheral Blood Stem Cell (PBSC)
13.3.3. Umbilical Cord Blood
13.3.4. Adipose Tissue
13.3.5. Others
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Musculoskeletal Disease
13.4.2. Cardiovascular Disease
13.4.3. Autoimmune Disease
13.4.4. Cancer
13.4.5. GvHD
13.4.6. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospital
13.5.2. Ambulatory Surgical Center
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Cell Source
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Allogeneic Stem Cell Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. Unmodified Stem Cell Transplant
14.2.2. T-cell Depleted Transplant
14.2.3. Cord Blood Transplant
14.2.4. Donor Lymphocyte Infusion (DLI)
14.3. Market Value Forecast, by Cell Source, 2017-2031
14.3.1. Bone Marrow
14.3.2. Peripheral Blood Stem Cell (PBSC)
14.3.3. Umbilical Cord Blood
14.3.4. Adipose Tissue
14.3.5. Others
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Musculoskeletal Disease
14.4.2. Cardiovascular Disease
14.4.3. Autoimmune Disease
14.4.4. Cancer
14.4.5. GvHD
14.4.6. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospital
14.5.2. Ambulatory Surgical Center
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Cell Source
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Allogeneic Stem Cell Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017-2031
15.2.1. Unmodified Stem Cell Transplant
15.2.2. T-cell Depleted Transplant
15.2.3. Cord Blood Transplant
15.2.4. Donor Lymphocyte Infusion (DLI)
15.3. Market Value Forecast, by Cell Source, 2017-2031
15.3.1. Bone Marrow
15.3.2. Peripheral Blood Stem Cell (PBSC)
15.3.3. Umbilical Cord Blood
15.3.4. Adipose Tissue
15.3.5. Others
15.4. Market Value Forecast, by Application, 2017-2031
15.4.1. Musculoskeletal Disease
15.4.2. Cardiovascular Disease
15.4.3. Autoimmune Disease
15.4.4. Cancer
15.4.5. GvHD
15.4.6. Others
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospital
15.5.2. Ambulatory Surgical Center
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Cell Source
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Mesoblast Limited
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Gamida Cell Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Novartis International AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Cellectis SA
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Magenta Therapeutics Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Fate Therapeutics Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Cynata Therapeutics Limited
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Kiadis Pharma N.V.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Takeda Pharmaceutical Company Limited
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. JCR Pharmaceuticals Co., Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Pluristem Therapeutics Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Celularity Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Lineage Cell Therapeutics Inc.
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. Nohla Therapeutics Inc.
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Orchard Therapeutics plc
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Product Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview
16.3.16. Other Prominent Players
16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.16.2. Product Portfolio
16.3.16.3. Financial Overview
16.3.16.4. SWOT Analysis
16.3.16.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings